Broadly Reactive SARS-CoV-2-Specific T-Cell Response and Participation of Memory B and T Cells in Patients with Omicron COVID-19 Infection
Table 1
Characteristics of the study population.
Parameters
Vaccinated Omicron-infected patients
Unvaccinated Omicron-infected patients
Unvaccinated SARS-CoV-2 (2020) Indian patients with mild infection
Uninfected controls
Study population
n = 15
n = 4
n = 45
n = 36
Age (median, range)
42 (18–72)
17 (7–28)
38 (15–75)
20 (18–26)
Gender (male/female)
8M/7F
0M/4F
24M/21F
26M/10F
Vaccination status
Covishield (ChAdOx1 nCoV-19)
COVAXIN (BBV152)
Pfizer (BNT162b2 mRNA)
Unvaccinated
Unvaccinated
Unvaccinated
n = 12 (6M/6F)
n = 1 (M)
n = 2 (1M/1F)
Status of infection
Asymptomatic (n = 9) Mild symptomatic (n = 3)
Asymptomatic (n = 1)
Asymptomatic (n = 1) Mild symptomatic (n = 1)
Asymptomatic (n = 3) Mild symptomatic (n = 1)
Asymptomatic (n = 23) Mild symptomatic (n = 22)
NA
Days post onset of illness (POD)
9 (2–17) days
NA
3 days
12 days
7 (0–17)
Status of reinfection
n = 2
n = 1
No
No
No
Infection post-vaccination days
119 (16–222)
248
115 (137–219)
NA
NA
Comorbid conditions (diabetes/HTN)
n = 3
No
No
No
No
S1RBD IgG status and titer
Positives (n = 12,100%) titer (1,000–>3,200)
Positive (n = 1) titer (2,000)
Positives (n = 2) titer (800–>3,200)
Positive (n = 2) titer (100–2,000)
NA
Anti-SARS-CoV-2 IgG antibody negatives
N Protein IgG status and titer
Positives (n = 10, 83.3%) titer (50–>3,200)
Positive (n = 1) titer (3,200)
Positive (n = 1) titer (50)
Negatives (n = 4) titer (<50)
COVID KAWACH IgG status and titer
Positives (n = 10, 83.3%) titer (100–>3,200)
Positive (n = 1) titer (3,200)
Positive (n = 1) titer (100)
Positives (n = 3) titer (100–6,400)
Positives (n = 45) titer (NA)
All the Omicron-infected cases had a milder course of infection and recovered eventually. M, male; F, female; NA, not-available; NA, not applicable; HTN, hypertension/hypotension (blood pressure).
